Cited by 573Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank

Open access

Patel, Aniruddh P., Wang, Minxian, Pirruccello, James P., Ellinor, Patrick T., Ng, Kenney, Kathiresan, Sekar, Khera, Amit V.·2021·Arteriosclerosis, Thrombosis, and Vascular Biology

DOI 10.1161/atvbaha.120.315291PMC PMC7769893

Open this paper in CoChat — free account Open PDF

Abstract

Objective: Lp(a) (lipoprotein[a]) concentrations are associated with atherosclerotic cardiovascular disease (ASCVD), and new therapies that enable potent and specific reduction are in development. In the largest study conducted to date, we address 3 areas of uncertainty: (1) the magnitude and shape of ASCVD risk conferred across the distribution of lipoprotein(a) concentrations; (2) variation of risk across racial and clinical subgroups; (3) clinical importance of a high lipoprotein(a) threshold to guide therapy. Approach and Results: Relationship of lipoprotein(a) to incident ASCVD was studied in 460 506 middle-aged UK Biobank participants. Over a median follow-up of 11.2 years, incident ASCVD occurred in 22 401 (4.9%) participants. Median lipoprotein(a) concentration was 19.6 nmol/L (25th–75th percentile 7.6–74.8). The relationship between lipoprotein(a) and ASCVD appeared linear across the distribution, with a hazard ratio of 1.11 (95% CI, 1.10–1.12) per 50 nmol/L increment. Substantial differences in concentrations were noted according to race—median values for white, South Asian, black, and Chinese individuals were 19, 31, 75, and 16 nmol/L, respectively. However, risk per 50 nmol/L appeared similar—hazard ratios of 1.11, 1.10, and 1.07 for white, South Asian, and black individuals, respectively. A high lipoprotein(a) concentration defined as ≥150 nmol/L was present in 12.2% of those without and 20.3% of those with preexisting ASCVD and associated with hazard ratios of 1.50 (95% CI, 1.44–1.56) and 1.16 (95% CI, 1.05–1.27), respectively. Conclusions: Lipoprotein(a) concentrations predict incident ASCVD among middle-aged adults within primary and secondary prevention contexts, with a linear risk gradient across the distribution. Concentrations are variable across racial subgroups, but the associated risk appears similar.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/atvbaha.120.315291

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0183-z · Cited by 2,953
Self-citation
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., Tardif, J.-C., Baum, S. J., Steinhagen-Thiessen, E., Shapiro, M. D., Stroes, E. S., Moriarty, P. M., Nordestgaard, B. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1905239 · Cited by 1,094
Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease
Tsimikas, S., Brilakis, E. S., Miller, E. R., McConnell, J. P., Lennon, R. J., Kornman, K. S., Witztum, J. L., & Berger, P. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043175 · Cited by 782
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis
Burgess, S., Ference, B. A., Staley, J. R., Freitag, D. F., Mason, A. M., Nielsen, S. F., Willeit, P., Young, R., Surendran, P., Karthikeyan, S., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1470 · Cited by 689
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31652-0 · Cited by 564
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.010 · Cited by 522
NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis
Tsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes‐Soffer, G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.014 · Cited by 519
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Khera, A. V., Everett, B. M., Caulfield, M. P., Hantash, F. M., Wohlgemuth, J., Ridker, P. M., & Mora, S. (2014) · Circulation · doi:10.1161/circulationaha.113.004406 · Cited by 461
Self-citation
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
Tsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460
Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups
Paré, G., Çaku, A., McQueen, M., Anand, S. S., Enas, E. A., Clarke, R., Boffa, M. B., Koschinsky, M. L., Wang, X., Yusuf, S., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.034311 · Cited by 385
Lipoprotein (a) measurements for clinical application
Marcovina, S. M., & Albers, J. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r061648 · Cited by 338
Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects
Virani, S. S., Brautbar, A., Davis, B., Nambi, V., Hoogeveen, R. C., Sharrett, A. R., Coresh, J., Mosley, T. H., Morrisett, J. D., Catellier, D., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.045120 · Cited by 325
Use of a Reference Material Proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to Evaluate Analytical Methods for the Determination of Plasma Lipoprotein(a)
Marcovina, S. M., Albers, J. J., Scanu, A. M., Kennedy, H., Giaculli, F., Berg, K., Couderc, R., Dati, F., Rifai, N., Sakurabayashi, I., et al. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.1956 · Cited by 315
Report of the national heart, lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions
Marcovina, S. M., Koschinsky, M. L., Albers, J. J., & Skarlatos, S. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.023689 · Cited by 288
Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention
Madsen, C. M., Kamstrup, P. R., Langsted, A., Varbo, A., & Nordestgaard, B. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312951 · Cited by 288
Elevated Lipoprotein(a) and Risk of Ischemic Stroke
Langsted, A., Nordestgaard, B. G., & Kamstrup, P. R. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.524 · Cited by 272
Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels
Emdin, C. A., Khera, A. V., Natarajan, P., Klarin, D., Won, H.-H., Peloso, G. M., Stitziel, N. O., Nomura, A., Zekavat, S. M., Bick, A. G., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.033 · Cited by 244
Self-citation
Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium
Waldeyer, C., Makarova, N., Zeller, T., Schnabel, R. B., Brunner, F. J., Jørgensen, T., Linneberg, A. R., Niiranen, T., Salomaa, V. V., Jousilahti, P., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx166 · Cited by 244
Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease
Tsimikas, S., & Hall, J. L. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.038 · Cited by 234
Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes
Gudbjartsson, D. F., Þorgeirsson, G., Sulem, P., Helgadóttir, A., Gylfason, A., Saemundsdottir, J., Björnsson, E., Norddahl, G. L., Jónasdóttir, Á., Jónasdóttir, A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.019 · Cited by 227
Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes
Lamina, C., & Kronenberg, F. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1041 · Cited by 225
Race Is a Key Variable in Assigning Lipoprotein(a) Cutoff Values for Coronary Heart Disease Risk Assessment
Guan, W., Cao, J., Steffen, B. T., Post, W. S., Stein, J. H., Tattersall, M. C., Kaufman, J. D., McConnell, J. P., Hoefner, D. M., Warnick, R., et al. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304785 · Cited by 219
Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice
Merki, E., Graham, M. J., Mullick, A. E., Miller, E. R., Crooke, R. M., Pitas, R. E., Witztum, J. L., & Tsimikas, S. (2008) · Circulation · doi:10.1161/circulationaha.108.786822 · Cited by 156
A New Serum Type System in Man — The Ld System
Berg, K. (1965) · Vox Sanguinis · doi:10.1111/j.1423-0410.1965.tb01404.x · Cited by 155
Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors
Tsimikas, S., Clopton, P., Brilakis, E. S., Marcovina, S. M., Khera, A., Miller, E. R., de Lemos, J. A., & Witztum, J. L. (2009) · Circulation · doi:10.1161/circulationaha.108.836940 · Cited by 151
Self-citation
smoothHR: An R Package for Pointwise Nonparametric Estimation of Hazard Ratio Curves of Continuous Predictors
Meira‐Machado, L., Cadarso-Suárez, C., Gudé, F., & Araújo, A. (2013) · Computational and Mathematical Methods in Medicine · doi:10.1155/2013/745742 · Cited by 150
Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting
Verbeek, R., Hoogeveen, R. M., Langsted, A., Stiekema, L. C. A., Verweij, S. L., Hovingh, G. K., Wareham, N. J., Khaw, K., Boekholdt, S. M., Nordestgaard, B. G., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy334 · Cited by 147
LPA Gene, Ethnicity, and Cardiovascular Events
Lee, S. R., Prasad, A., Choi, Y. S., Xing, C., Clopton, P., Witztum, J. L., & Tsimikas, S. (2016) · Circulation · doi:10.1161/circulationaha.116.024611 · Cited by 141
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
Graham, M. J., Viney, N., Crooke, R. M., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r052258 · Cited by 133
Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice
Merki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W., Mullick, A. E., Lee, R., Willeit, P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.052 · Cited by 124
Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History
Patel, A. P., Wang, M., Fahed, A. C., Mason‐Suares, H., Brockman, D., Pelletier, R. C., Amr, S. S., Machini, K., Hawley, M. H., Witkowski, L., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.3959 · Cited by 102
Self-citation
Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries
Zekavat, S. M., Ruotsalainen, S., Handsaker, R. E., Alver, M., Bloom, J., Poterba, T., Seed, C., Ernst, J., Chaffin, M., Engreitz, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04668-w · Cited by 98
Self-citation
Studies on an extra pre-beta lipoprotein fraction.
Dahlén, G., Ericson, C., Furberg, C. D., Lundkvist, L., & Svärdsudd, K. (1972) · PubMed · Cited by 85
Lipoprotein(a) and Apolipoprotein(a) Isoforms
Guerra, R., Yu, Z., Marcovina, S. M., Peshock, R. M., Cohen, J. C., & Hobbs, H. H. (2005) · Circulation · doi:10.1161/01.cir.0000159263.50305.bd · Cited by 80
Single-Nucleotide Polymorphisms in LPA Explain Most of the Ancestry-Specific Variation in Lp(a) Levels in African Americans
Deo, R. C., Wilson, J. G., Xing, C., Lawson, K., Kao, W. H. L., Reich, D., Tandon, A., Akylbekova, E. L., Patterson, N. J., Mosley, T. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014581 · Cited by 79
Race-Based Differences in Lipoprotein(a)-Associated Risk of Carotid Atherosclerosis
Steffen, B. T., Thanassoulis, G., Duprez, D. A., Stein, J. H., Karger, A. B., Tattersall, M. C., Kaufman, J. D., Guan, W., & Tsai, M. Y. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312267 · Cited by 75
Genetic Variants in the Apolipoprotein(a) Gene and Coronary Heart Disease
Li, Y., Luke, M. M., Shiffman, D., & Devlin, J. J. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.959601 · Cited by 65
Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study
Verbeek, R., Boekholdt, S. M., Stoekenbroek, R. M., Hovingh, G. K., Witztum, J. L., Wareham, N. J., Sandhu, M. S., Khaw, K., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p066258 · Cited by 44
LIPOPROTEIN(A), CORONARY ARTERY CALCIFICATION AND CARDIOVASCULAR EVENTS: A COHORT STUDY FROM CHINA
Wu, N., Liu, S.-L., Rozi, R., Shi, H.-W., Dong, Q., Dong, Q., Gao, Y., Guo, Y., & Li, J. (2020) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(20)30746-4 · Cited by 2

Sorted by citations

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,284
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
Reyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836

See all 573

Authors: Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V.
Affiliations: Broad Institute (US)
IBM Research - Cambridge (United States) (US)
Corresponding author: Khera, Amit V.
ORCID: Patel, Aniruddh P.
Wang, Minxian
Pirruccello, James P.
Ellinor, Patrick T.
Ng, Kenney
Kathiresan, Sekar
Khera, Amit V.
Venue: Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2021-01
Volume: 41
Issue: 1
Pages: 465-474
ISSN: 1079-5642 (ISSN-L)
1524-4636
DOI: 10.1161/atvbaha.120.315291
PMC: PMC7769893
OpenAlex: W3097307979
Cited by: 567
References: 50
Citations by year: 2026: 135 · 2025: 147 · 2024: 110 · 2023: 89 · 2022: 60 · 2021: 25
FWCI: 39.95
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: other-oa
Locations: Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion, other-oa)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: American Heart Association (R01 HL128914, 18SFRN34110082)
Massachusetts General Hospital
Broad Institute
Fondation Leducq (K24HL105780, 18SFRN34110082, 1RO1HL092577, T32HL007208, 14CVD01, R01HL128914)
Medical Research Council (MC_PC_17228)
National Heart, Lung, and Blood Institute (1RO1HL092577, R01HL128914, K24HL105780, R01HL092577, T32HL007208)
National Human Genome Research Institute (K08HG010155, 18SFRN34110082)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: lipoprotein(a), atherosclerotic cardiovascular disease, incident cardiovascular events, racial differences, risk gradient, primary prevention, secondary prevention, middle-aged adults, UK Biobank
MeSH terms: Race Factors, Heart Disease Risk Factors, Adult, Aged, Female, United Kingdom, Humans, Male, Middle Aged, Primary Prevention, Prognosis, Time Factors, Biomarkers, Incidence, Lipoprotein(a), Biological Specimen Banks, Risk Assessment, Atherosclerosis, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks